Background Although the need for corticosteroids in acute severe asthma is well established the appropriate dose is not known. Methods The response to intravenous hydrocortisone 50 mg (low dose), 100 mg (medium dose), and 500 mg (high dose), administered every six hours for 48 hours and followed by oral prednisone, was compared in patients with acute asthma in a double blind randomised study. After initial emergency treatment with bronchodilators subjects received oral theophylline or intravenous aminophylline and nebulised salbutamol four hourly. The widely accepted regimen of intravenous hydrocortisone 200-300 mg every six hours appears to be based on work by Collins et al in 1975.2 On the basis of earlier descriptive work on cortisone metabolism in steroid dependent asthmatic patients during acute severe episodes,3 Collins suggested that doses of corticosteroids equivalent to hydrocortisone 300 mg four times a day would achieve "therapeutic" serum concentrations. The authors found that higher doses were no more effective,4 and this has been confirmed in other studies.' Few studies have explored the response to lower doses.89
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Apart from the problem of cost, high doses of corticosteroids may cause more steroid related side effects than low doses. Shee,'°for example, suggests that a high total dose may be a factor in acute myopathy in patients with acute severe asthma.
We have therefore compared, in a double blind randomised trial, three doses of intravenous hydrocortisone six hourly in patients with acute severe asthma. The doses were 50 mg (low dose, equivalent to prednisone 50 mg a day), 200 mg (medium dose), and 500 mg (high dose). Parenteral treatment was followed by matched low, medium, or high doses of oral prednisone (20, 40, or 60 m daily), which were then tapered over 12 days.
Methods
We studied subjects with acute severe asthma presenting to the accident and emergency departments of two general hospitals. Subjects were aged 18-65 years with an unequivocal history of asthma and previously or subsequently showed short term variability in forced expiratory volume in one second (FEVy) of at least 15%. Patients with complicating factors such as a pneumothorax or consolidation on the chest radiograph, asthma that warranted admission to the intensive care unit, or other major illness were excluded, as were subjects who had been taking more than 10 mg prednisone a day before admission. The study received the approval of the ethics committee and all subjects gave informed consent.
The patients assessed the severity of their dyspnoea on a 100 mm visual analogue scale"
(100 mm = no symptoms; 0 mm = maximum symptoms) and recorded peak expiratory flow Figure 2 Mean (SE) FEV, as a percentage of the predicted value before and after bronchodilator treatment (BD) for the low, medium, and high dose groups in subjects whose FEV, after initial treatment in the accident and emergency department (A and E) was less than 30% (n = 11, 13, and 10). There was no difference between treatment groups at any time. Except for post BD day I -pre BD day 2 all values within each treatment group are significantly different from the preceding and subsequent measurements (p < 0 01).
When the 34 subjects whose FEVy after treatment in the accident and emergency room was less than 30% predicted (mean 21% (6%)) had their data analysed separately, there were still no differences related to treatment. At 48 hours (after salbutamol) FEVy was 62 (27), 60 (22), and 55 (22) % predicted for the low (n = 11), medium (n = 13), and high dose (n = 10) group respectively (fig 2) .
Although the study had planned to measure PEF and visual analogue scale score for 14 days, dropout rates were high and by day 12 only 40 patients (67% of original group) were still recording values-13 (59%) in the low dose, 15 (75%) in the medium dose, and 12 (50%) in the high dose group. Morning prebronchodilator PEF (fig 3) improved rapidly after admission, most of the change occurring in the first two days. A trend towards a higher PEF in patients who received the higher dose of prednisone appeared towards the end of the study but the difference did not reach statistical significance. On day 12, mean (SD) morning prebronchodilator PEF values (% predicted) were 78 (27), 78 (27), and 95 (33) in the low, medium, and high dose groups. Mean afternoon postbronchodilator values showed no such trend, mean (SD) % predicted being 87 (31), 102 (24), and 99 (17) in the three groups.
No effect of medication dose on daily variability in PEF-that is, (best PEF -worst PEF)/best PEF)-was observed, mean (SD) % in the low, medium, and high dose groups being 10 (18), 27 (27), and 26 (54).
Corticosteroid dose did not affect subjective perception of asthma, which improved rapidly after admission (fig 4) . The mean (SD) visual analogue scale dyspnoea scores before treatment were 18 (20), 31 (21), and 26 (19) mm in the low, medium, and high dose groups and 65 (28), 67 (24), and 70 (23) mm after initial treatment in the accident and emergency department. On the afternoon of the second day of hydrocortisone treatment the visual analogue scale scores were 84 (24), 92 (16) , and 88 (15) mm in the low, medium, and high dose groups and in the afternoon after 12 days of treatment 85 (25), 92 (19), and 96 (8) mm.
Discussion
In this study of patients with acute severe asthma we have been unable to show any difference in the rate of recovery between subjects given low, medium, and high doses of hydrocortisone. The low dose of hydrocortisone (50 mg every six hours) is equivalent to 50 mg of prednisone a day and the medium dose (200 mg every six hours) is a commonly used inpatient parenteral dose, whereas the high dose (500 mg every six hours) is an empirical high dose. Neither perception ofbreathlessness (visual analogue scale), nor objective measures (FEVy, PEF) were influenced by the dose of hydrocortisone. No trend was evident between drug doses at 48 hours. Although we cannot definitely exclude a type II error, it seems unlikely that larger groups of patients would change the results.
Apart from documenting changes over an initial two days, the study attempted to measure the additional effect of varying doses of prednisone over the following 12 days.
Although interpretation is limited by the number of subjects who failed to complete their records, there was a trend favouring the group having the highest dose of steroid by day 12 
